Khaled Musallam on Management of Transfusion-Dependent β-Thalassaemia in LMICs
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared on LinkedIn:
”On the first day of 2026, I’m delighted to share one of my favourite pieces of work—published today in The Lancet Haematology and featured on the cover.
This Viewpoint introduces a practical decision matrix to help prioritise novel therapies for thalassemia—including disease-modifying and gene therapies—based on need, benefit, and risk, particularly in settings where access remains limited.
It also proposes realistic alternatives when standard options are not available.
The work builds on Thalassaemia International Federation guidelines, the best available trial and real-world evidence, and expert consensus from a truly global group of haematologists, transplant physicians, patient representatives, translational scientists, and trialists—bringing together 200+ years of collective clinical experience across Asia, the Middle East, Europe, and North America.
Grateful to an exceptional group of co-authors and hopeful this framework helps support more equitable, evidence-based care for patients worldwide.”
Read the full article in The Lancet Hematology.
Article: Management of transfusion-dependent β-thalassaemia in the era of novel therapies: a prioritisation-based matrix for settings with limited resources
Authors: Khaled Musallam, Sujit Sheth, Maria Domenica Cappellini, Farrukh Shah, Stefano Rivella, Vijay G Sankaran et al.
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 15, 2026, 10:49Aurelio Maggio: How Is The Treatment Landscape Of Thrombotic Thrombocytopenic Purpura Evolving?
-
Jun 15, 2026, 10:49Marek Mráz: A Landmark EHA 2026 for Our Lab
-
Jun 15, 2026, 10:32Magnus Ek: Operational Excellence in Delivering Seamless Access for 17,000 Delegates at EHA 2026 Congress
-
Jun 15, 2026, 10:15Carol Bewick: Why the Global Community Makes EHA 2026 Unforgettable
-
Jun 15, 2026, 10:07Habib Bennaceur: Driving Haemoglobinopathies Progress Across Multiple Clinical Programmes At EHA 2026
-
Jun 14, 2026, 22:49Cihan Ay: From First Oral Presentation to Pro and Con Debate – A 20-Year EHA Journey
-
Jun 14, 2026, 19:54Tareq Abadl: What Happens If You Transfuse the Wrong Blood Group?
-
Jun 14, 2026, 19:46Amber Yates: Stretching Scientific Muscles in Areas of Hematology – Day 2 at EHA 2026
-
Jun 14, 2026, 19:41Peter Loffelhardt: Thousands of People Coming in – Second Day at EHA 2026